|A safe lithium mimetic for bipolar disorder.|
|Jump to Full Text|
|PMID: 23299882 Owner: NLM Status: MEDLINE|
|Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects. It is likely that a small molecule could be found with lithium-like efficacy but without toxicity through target-based drug discovery; however, therapeutic target of lithium remains equivocal. Inositol monophosphatase is a possible target but no bioavailable inhibitors exist. Here we report that the antioxidant ebselen inhibits inositol monophosphatase and induces lithium-like effects on mouse behaviour, which are reversed with inositol, consistent with a mechanism involving inhibition of inositol recycling. Ebselen is part of the National Institutes of Health Clinical Collection, a chemical library of bioavailable drugs considered clinically safe but without proven use. Therefore, ebselen represents a lithium mimetic with the potential both to validate inositol monophosphatase inhibition as a treatment for bipolar disorder and to serve as a treatment itself.|
|Nisha Singh; Amy C Halliday; Justyn M Thomas; Olga V Kuznetsova; Rhiannon Baldwin; Esther C Y Woon; Parvinder K Aley; Ivi Antoniadou; Trevor Sharp; Sridhar R Vasudevan; Grant C Churchill|
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: Nature communications Volume: 4 ISSN: 2041-1723 ISO Abbreviation: Nat Commun Publication Date: 2013|
|Created Date: 2013-01-09 Completed Date: 2013-06-20 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 101528555 Medline TA: Nat Commun Country: England|
|Languages: eng Pagination: 1332 Citation Subset: IM|
|University of Oxford, Department of Pharmacology, Mansfield Road, Oxford OX1 3QT, UK.|
|APA/MLA Format Download EndNote Download BibTex|
Azoles / chemistry, pharmacology, therapeutic use
Behavior, Animal / drug effects
Bipolar Disorder / drug therapy*, enzymology, pathology
Blood-Brain Barrier / drug effects, enzymology, pathology
Enzyme Inhibitors / chemistry, pharmacology, therapeutic use
Inositol / deficiency, pharmacology
Lithium / pharmacology, therapeutic use*
Mice, Inbred C57BL
Organoselenium Compounds / chemistry, pharmacology, therapeutic use
Phosphoric Monoester Hydrolases / antagonists & inhibitors, metabolism
|BB/D012694/1//Biotechnology and Biological Sciences Research Council; BB/I532929/1//Biotechnology and Biological Sciences Research Council; BB/J021547/1//Biotechnology and Biological Sciences Research Council|
|0/Azoles; 0/Enzyme Inhibitors; 0/Organoselenium Compounds; 40X2P7DPGH/ebselen; 6917-35-7/Inositol; 7439-93-2/Lithium; EC 3.1.3.-/Phosphoric Monoester Hydrolases; EC 220.127.116.11/myo-inositol-1 (or 4)-monophosphatase|
Journal ID (nlm-journal-id): 101528555
Journal ID (pubmed-jr-id): 37539
Journal ID (nlm-ta): Nat Commun
Journal ID (iso-abbrev): Nat Commun
nihms-submitted publication date: Day: 3 Month: 12 Year: 2012
Print publication date: Year: 2013
pmc-release publication date: Day: 01 Month: 7 Year: 2013
Volume: 4First Page: 1332 Last Page: 1332
PubMed Id: 23299882
|A safe lithium mimetic for bipolar disorder|
|Amy C. Halliday|
|Justyn M. Thomas|
|Esther C. Y. Woon|
|Parvinder K. Aley|
|Sridhar R. Vasudevan*|
|Grant C. Churchill*|
|University of Oxford, Department of Pharmacology, Mansfield Road, Oxford OX1 3QT, United Kingdom
|Correspondence: Corresponding authors:email@example.com
*These authors contributed equally.
Author contributions: G.C.C. conceived the project. N.S. and A.C.H. carried out the expression of the wild type IMPase and A.C.H., N.S. and R.B. of the C218A mutant. N.S. and E.C.Y.W. carried out the mass spectrometry. J.M.T. and N.S. optimized the enzymology and J.M.T. performed the screening, identification and initial characterization of ebselen. N.S., O.K. and R.B. carried out the reversibility and sulfhydryl agent experiments. P.K.A provided help and advice with all the in vitro experiments. N.S. carried out the ex vivo experiments. A.C.H. and R.B. carried out measurements of inositol with nuclear magnetic resonance. N.S., A.C.H., S.R.V. and I.A. carried out the behavioural experiments. T.S. helped design and interpret the behavioural and molecular experiments. N.S. and G.C.C. wrote the paper with contributions from T.S. and all authors contributed to final edits. G.C.C. and S.R.V. managed the project and are joint senior authors.
Bipolar disorder affects 1-3% of the population and the most effective treatment for stabilizing mood is lithium 1. Lithium is also the only agent that reduces suicidal thoughts and actions 2. Unfortunately, lithium is toxic at only twice the therapeutic dosage and has many undesirable side effects including weight gain, thirst, tremor and kidney damage 3. To develop a lithium mimetic—ideally a drug with its therapeutic action but without its disadvantages—would require an understanding of lithium’s mechanism of action, which, even after six decades of use 4, remains controversial 5. Lithium displaces magnesium ions and inhibits at least 10 cellular targets, all of which are components of intracellular signalling pathways5. However, targets inhibited by lithium at therapeutically relevant concentrations (0.6-1 mM) narrows the targets to two: glycogen synthase kinase 3ß6 and inositol monophosphatase 7-9. Both putative targets have experimental evidence for and against them based on genetics and pharmacology6,9-12. Additionally, several chemically distinct bipolar medications (lithium, valproic acid and carbamazapine) all have a common mechanism of action affecting the inositol cycle13. Inhibition of inositol monophosphatase by lithium led to Berridge’s ‘inositol depletion hypothesis’ that suggests that Ins1P accumulates and inositol is depleted7. Given that in neurons regeneration of phosphatidylinositol 4,5-bisphosphate requires recycling of inositol from Ins1P, lithium dampens signalling in cells with overactive signalling through pathways using a G-protein-coupled receptor linked to phospholipase C7.
IMPase remains a potential therapeutic target for bipolar disorder, but its validation requires small molecule inhibitors. However, little progress has been made in regard to inhibitors since a large effort by Merck yielded a potent (IC50 300 nM) antagonist (L-690,330) but neither it nor its esterified prodrug (L-690,488) was bioavailable 14,15. We now report that ebselen inhibits IMPase and acts as a lithium mimetic in mouse models of bipolar disorder.
To identify an inhibitor of IMPase, we expressed human IMPase in bacteria and used it in an assay to screen the NIH Clinical Collection provided through the National Institutes of Health Molecular Libraries Roadmap Initiative 16. Compounds in this collection have a history of use in human clinical trials, are drug-like with known safety profiles and may even be appropriate for direct human use in new disease areas (www.nihclinicalcollection.com). A primary screen at 100 μM of each drug in the collection identified ebselen (Fig. 1a) as an inhibitor of IMPase, and we characterized it further with a full concentration-response curve (Fig. 1b). The potency of ebselen against IMPase (IC50 1.5 μM) compared favourably to that of the known but poorly bioavailable inhibitor L-690,33014 (IC50 0.3 μM) and was greater than that of lithium (IC50 0.8 mM; Fig. 1b). Importantly, the greater potency of ebselen for IMPase (Fig. 1b) compared to glycogen synthase kinase 3ß (Fig. 1c) demonstrates selectivity, making ebselen of diagnostic use in determining the therapeutic potential of IMPase inhibition.
As increasing concentrations of ebselen decreased Vmax with little effect on Km (Fig. 1d,e) the inhibition is not competitive17. Inhibition of IMPase by ebselen was not fully relieved by dilution (20 μM to 0.2 μM ebselen; Fig. 1f) even after a time course for recovery extending to 25 h (Fig. 1g), thus indicating that inhibition is, for practical purposes, irreversible. (A reversible inhibitor would lose potency upon dilution due to mass action promoting dissociation17.) As irreversible inhibition often arises from covalent binding, we looked for direct evidence of ebselen binding to IMPase. Mass spectrometry revealed that a mixture of IMPase and ebselen formed complexes heavier than pure IMPase dimer by the mass of one or two ebselen molecules under both denaturing and non-denaturing conditions (Fig. 1h), supporting covalent binding and 1:1 stoichiometry per monomer. In contrast, a mixture of IMPase and the reversible inhibitor L-690,33014 formed heavier complexes under non-denaturing conditions, but not under denaturing conditions (Fig. 1h).
Ebselen contains selenium (Fig. 1a), which can form a selenylsulfide (–Se–S–) bond18,19. For bovine IMPase, alkylation of cysteine 218 with the non-selective agent N-ethylmaleimide inhibited activity20. In bovine IMPase, cysteine 218 is near the active site residue aspartate 220, which is required for magnesium ion coordination and catalysis20. The position of this cysteine is conserved in both the mouse and human isoforms based on its crystal structure21. To test the importance of this cysteine in mediating ebselen inhibition, we constructed a human IMPase with a cysteine to alanine mutation (C218A). The C128A mutant was indeed less sensitive to ebselen inhibition, based on the increase in IC50 for ebselen (Fig. 1i) and a smaller decrease in Vmax (Fig. 1j,k). Furthermore, an analogue ebselen in which the selenium is substituted with sulphur (ebsulfur; Fig. 1a) weakly inhibited IMPase (Fig. 1l), whereas a selenium-containing compound with similar electrophilic reactivity (dibenzyldiselenide; Fig. 1a) had no inhibitory effect (Fig. 1l). These data demonstrate that inhibition of IMPase by ebselen requires not just the presence of an electrophilic selenium atom but also an appropriate chemical scaffold. Unlike the case for most other proteins when covalently linked to ebselen18,19,22, inactivation of IMPase was not reversed by post-incubation with the sulfhydryl reducing agents glutathione and dithiothreitol (Fig. 1m). Pre-incubation of ebselen with the reducing agents did, however, reduce inhibition (Fig. 1n) as described in detail below.
To determine whether ebselen can cross the blood–brain barrier and thus be pharmacologically active in mouse brain, as reported for rat23, we exploited the irreversible inhibition property of ebselen in an ex vivo method based on IMPase activity in brain homogenate (Fig. 2a). As the initial experiments that identified ebselen as an inhibitor used recombinant human IMPase (Fig. 1b), we first needed to ensure that recombinant mouse IMPase was enzymatically active. Recombinant mouse IMPase was inhibited by lithium and L-690, 330 and ebselen (Fig. 2b). Having validated that ebselen inhibited the mouse form of IMPase, we demonstrated that in homogenates of mouse brain, IMPase activity was detectable and inhibited by lithium, L-690,330 and ebselen (Fig. 2c). In an ex vivo experiment, IMPase activity was measured in brain homogenates prepared at various times after intraperitoneal injection of ebselen (Fig. 2a)24. Over time, IMPase inhibition developed and then returned to control levels (Fig. 2d,e). Therefore, systemic administration of ebselen inhibits IMPase in mouse brain in whole animals.
That IMPase inhibition by ebselen was detected in the ex vivo experiments (Fig. 2d,e) is revealing in regard to the likely chemical form of ebselen in intact cells in vivo, as its selenium atom can exist in higher or lower oxidation states, and these have different reactivities18,19. Incubation of ebselen with reduced glutathione forms ebselen–glutathione selenenylsulphide, whereas incubation with dithiothreitol reduces ebselen to its selenol and diselenide (Fig. 1a,l)18,19. When we pre-incubated ebselen with these reducing agents the reduced forms of ebselen (confirmed by mass spectrometry) were weaker inhibitors of IMPase (Fig. 1n), likely because they are less reactive with cysteines18. Therefore, to obtain inhibition of IMPase with ebselen in vivo a fraction of ebselen must exist in a non-conjugated free form in the oxidation state shown in Fig. 1a, despite an intracellular environment with millimolar concentrations of reduced glutathione25.
To determine whether ebselen was affecting the function of the central nervous system, we investigated the effect of ebselen on the responses mediated by the serotonergic 5-HT2 receptor26. In humans, lithium reduces phosphoinositide cycle-coupled 5-HT2 receptor function27, and this may be linked to lithium’s antidepressant action. Lithium also reduces 5-HT2 receptor function in mouse as modelled by a 5-HT2 agonist-evoked head-twitch response28. This is mediated by the prefrontal cortex29, which is believed to be the target of lithium in the treatment of bipolar disorder30. Ebselen decreased 5-HT2 agonist-induced head twitches in a dose-dependent manner (Fig. 3a), and this was associated with decreased expression of Arc mRNA (a molecular marker of neural activity26) in the prefrontal cortex (Fig. 3b) and cingulate cortex (Fig. 3c). Thus, ebselen attenuates a cortically mediated 5-HT2 receptor response that is linked to phosphoinositide turnover, as would be predicted for an inhibitor of IMPase.
Rodent behaviours are used to model bipolar disorder, and typically focus on either the manic or the depressive pole31. The ‘learned helplessness’ aspect of depression is often modelled with the forced swim test. In this model, ebselen has recently been shown to exhibit anti-depressant action32. Given these findings, we investigated the effect of ebselen in lithium-sensitive mouse models of mania33. In the open field test (Fig. 3d), rearing was decreased by ebselen over time and then returned to baseline (Fig. 3e), a time course that paralleled that for IMPase inhibition in the ex vivo assay (Fig. 2e), as well as plasma ebselen concentrations in humans after oral administration34. Rearing is an exploratory behaviour that correlates with impulsivity33, which in turn correlates with suicidal thoughts and actions35. Mania has also been modelled by amphetamine-induced hyperactivity (Fig. 3f)33,36. Similarly to lithium37, ebselen reduced amphetamine-induced hyperactivity in a manner that depended on both the dose of amphetamine and the dose of ebselen (Fig. 3g), as is the case for lithium37. Baseline mobility was not significantly reduced (one-tailed, paired t-tests: amphetamine 2 mg/kg and ebselen 5 mg/kg, p=0.24; amphetamine 4 mg/kg and ebselen 5 mg/kg, p=0.08).
Finally, if ebselen were mimicking lithium by inhibition of IMPase (and therefore inositol depletion), then one would expect ebselen’s effects to be circumvented by administration of exogenous inositol. This reversal is diagnostic of the ‘inositol depletion hypothesis’ if the addition of inositol re-establishes normal phosphatidylinositol 4,5-bisphosphate signalling7,8,38. We injected inositol intracerebroventricularly (Fig. 4a), and this reversed the effects of ebselen in models of both rearing (Fig. 4b) and amphetamine-induced mobility (Fig. 4c). Furthermore, mice injected intraperitoneally with ebselen, showed a decrease in brain levels of inositol 1 h after administration (Fig. 4d,e) providing direct evidence for inositol depletion. Combined, these results are consistent with the known ability of inositol to reverse the behavioural effects of lithium8,9,38 and support the inositol depletion hypothesis7.
Despite 60 years of use since its discovery as a mood stabilizer4, lithium remains the gold standard for the treatment of bipolar disorder1. Although combination therapy with an antidepressant is used to treat bipolar disorder, there is a risk of precipitating mania39. Uniquely, lithium is the only drug reported to reduce suicidal thoughts and behaviour2. Lithium is less than ideal, however, due to its undesirable side effects and toxicity. Therefore, there is a crucial need for drugs that are safe and efficacious for the treatment of bipolar disorder. Currently, drugs fail clinical trials for primarily safety or efficacy40. Ebselen, is known to be clinically safe34,41 and hence its efficacy should be tested.
Ebselen exhibits lithium-like actions at many levels including enzymatic, inositol recycling and animal behaviour making it the best lithium mimetic reported to date5. Additionally, ebelen is bioavailable, blood-brain barrier permeant and safer than lithium based on cellular toxicity42 and Phase 1-3 clinical trials34,41. Ebselen exhibits a polypharmacology profile (http://mli.nih.gov/mli/mlp-probes/) that would be predicted to be beneficial in its role as a lithium mimetic because it directly inhibits the putative therapeutic targets of lithium including IMPase and protein kinase C43 as well as being an antioxidant and inhibitor of cyclooxygenases that promotes neuronal survival44. Polypharmacology is much more common than previously appreciated45. Moreover, polypharmacology is now a desirable property46,47, for example, antipsychotics hitting multiple targets were more efficacious than drugs that were selective48.
Inhibition of IMPase by ebselen is covalent and irreversible. Traditionally, covalent drugs have been disfavoured due to risks relating to immunogenicity49. However, covalent binding alone is not sufficient to cause problems50 and many marketed drugs act covalently49, demonstrating that such risks are compound specific. Importantly, ebselen has a good safety profile in all animal and human experiments reported to date34,41. Moreover, the irreversible action of ebelen on IMPase offers several advantages, as is that case for all irreversible drugs49,51,52. One is that an irreversible inhibition cannot be overcome by accumulation of substrate. Additionally, irreversible inhibition can interact with pharmacokinetic effects to prolong ebselen’s duration of action and increase its selectivity for IMPase. After dosing, the decreasing concentration of ebselen will decrease its inhibition of all its reversible secondary targets. In contrast, IMPase will remain inhibited until new enzyme is synthesized. Such a scenario is known to be the case for many marketed drugs that are covalent and irreversible inhibitors including the well known drugs aspirin, clopidogrel and omeprazole49.
There is an increasingly urgent need for new drugs for the treatment of mental illness, especially given that many large pharmaceutical companies have pulled out of these areas due to high costs and failure rates39,53 prompting speculation as to where new drugs will come from for treating disorders of the central nervous system54,55. Although there is no single solution, repurposing of drugs from their original use to a new use is being strongly promoted by government initiatives such as that announced by the NIH16,56,57. Given that ebselen has been in clinical trials34,41, ebselen offers all the promise of drug repurposing58.
Murine MmImpa1 and human HsImpa1 were amplified from cDNA clones (IMAGE clones 6413389 and 3682657, respectively; Source Bioscience, Cambridge, UK). Cloning and protein expression were carried out as reported21,59. Semi-purified recombinant protein was obtained by heating lysed-cell supernatant (68°C, 1 h) and centrifugation (30,000 g, 30 min, 4°C).
Site directed mutagenesis of cysteine 218 was carried out using the Stratagene QuickChange kit. Protein was expressed as before, but without sorbitol and betaine.
Phosphate hydrolyzed from Ins1P was detected using the malachite green assay. For the in vitro assays, recombinant HsIMPase (10 ng/well) or MmIMPase (30 ng/well) was incubated (1 h, 37°C) with Ins1P (1mM) in 20 μL Tris buffer (50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 150 mM KCl, 0.5 mg/mL BSA and 0.01% v/v Triton X pH 7.4). Absorbance was measured at 595 nm for samples and phosphate standards. For the ex vivo assays, brain homogenate (0.5 mg/mL) was incubated (37°C, 1 h) with Ins1P (0.1-2.4 mM) in the presence or absence of LiCl (30 mM) to determine IMPase-specific activity.
The NIH Clinical Collection of 450 compounds was provided by the National Institute of Health16 and purchased from BioFocus DPI. Compounds (100 μM) were screened at three concentrations of Ins1P. Initial hits were confirmed with concentration–inhibition curves spanning six orders of magnitude. Subsequent experiments used ebselen from Fisher Scientific. For compound screening, compound at 100 μM (in 0.2% v/v DMSO) was incubated with IMPase (10 min, room temperature) in buffer, before addition of Ins1P (1 mM) to a final volume of 20 μL and further incubated (37°C, 1 h). Phosphatase concentration was determined by the malachite green assay. LiCl and L-690,330 (Tocris) were used as positive controls.
Ebselen (250 μM) was treated with 0.25 M dithiothreitol (DTT) or 5 mM GSH; reduced ebselen (final concentration 50 μM) was incubated (1 h, room temperature) with HsIMPase before addition of Ins1P (0.1-3 mM) and further incubation (1 h, 37°C). Enzyme activity was determined by the malachite green assay.
HsIMPase (1 μg/well) was incubated with 20 μM drug for varying times before dilution to 10 ng/well, addition of Ins1P and further incubation (1 h, 37°C). Enzyme activity was determined by the malachite green assay.
Conditions were as described above, except that 2 μL of reductant (50 mM DTT or 1 mM GSH) was added to each well, after incubation of IMPase with ebselen.
IMPase (100 μM) was desalted using a Bio-Spin 6 Column (Bio-Rad) in 15 mM ammonium acetate (pH 7.5) and incubated (room temperature, 15 min) with 10 mM MgCl2 prior to non-denaturing electrospray ionization mass spectrometry analysis (Q-TOF micro, Micromass). Data were processed with MASSLYNX 4.0 (Waters). To investigate IMPase ligand binding, mass spectrometry was used as described60, but with an additional mild denaturing step. HsIMPase (100 μM) was incubated with 100 μM drug (10 min) then diluted (1:10) in 15 mM ammonium acetate buffer (pH 7.4) with 0.1% v/v formic acid. This solution was then subjected to mass spectroscopy.
All studies used 20-25 g 10-12 week old male C57Bl6 mice (Harlan Olac, UK). Mice were housed with 12 h light-dark cycles with free access to standard lab chow and water. Experiments were carried out in accordance with UK Home Office Animals (Scientific Procedures) Act (1986) and associated code of practice guidelines. Animals were dosed intraperitoneally (i.p.) at 10 μL/g, unless otherwise specified. Lithium was dosed i.p. at 67 μL/g.
Mice were injected with ebselen (10 mg/kg) or vehicle (4% w/v hydroxypropyl ß-cyclodextrin) and left for varying amounts of time before euthanization by cervical dislocation, or by CO2 followed by cervical dislocation. Brains were removed and frozen on dry ice immediately. One hemisphere was homogenized using a Precellys 24 bead mill homogenizer (Stretton) and diluted in Tris buffer (50 mM Tris HCl, 3 mM MgCl2, 150 mM KCl, 1 mM EGTA, 0.01% v/v Triton X pH 7.4) to a final concentration of 0.5 mg/mL.
Mice were euthanized by cervical dislocation 1 h after administration of ebselen (10 mg/kg) or vehicle (4% w/v hydroxypropyl ß-cyclodextrin), then brains were extracted and frozen immediately on dry ice. Brains were weighed then homogenized using a Precellys 24 bead mill homogenizer (Stretton). Acetonitrile was added to homogenate (1:1 v/v) to precipitate protein, the sample was centrifuged (13,000×g, 10 min), and the supernatant was prepared for NMR by lyophilization and reconstitution in D2O with 0.008% w/v 3- (trimethylsilyl)propionic 2233d acid sodium salt (600 mg/mL).
Mice were treated with ebselen or vehicle and immediately placed in Linton AM1053 X, Y, Z IR Activity Monitor (San Diego Instruments) for 1 h to habituate. Mice were then injected with D-amphetamine/saline and returned to the cage, and activity was monitored for an additional 1 h.
Mice were injected with ebselen (10 mg/kg) or vehicle (4% w/v hydroxypropyl ß-cyclodextrin) and left for varying amounts of time before being placed in the Linton AM1053 X, Y, Z IR Activity Monitor (San Diego Instruments) for 30 mins while their activity was monitored. Rearing was measured by counting the number of beam breaks in upper grid.
Inositol reversal experiments were performed as described38. With mice under isoflurane-induced general anaesthesia, a guide cannula was stereotaxically implanted to 1 mm above the injection site in the lateral ventricle, and held in place with dental cement (Aqualox). Mice were left to recover for 7 days before behavioural studies were carried out. Inositol (5 or 1 μL of a supersaturated solution ≥ 278 mM) or control (0.9% w/v NaCl) was injected intracerebroventicularly, then 24 h later amphetamine-induced hyperactivity was assessed as described above. Group means were compared with pre-planned t-tests, one-tailed or paired as appropriate.
Mice were placed in an arena and left to acclimatize to the novel environment. After 1 h, they were injected with vehicle or ebselen (5 or 10 mg/kg) followed 1 h later by the non-selective 5HT2A agonist 1- (2,5-dimethoxy-4 iodophenyl)-2-aminopropane (DOI, 2 mg/kg). Head twitches were recorded 5 min after agonist injection for 15 min. Mice were constantly monitored by a video camera, and behavioural recordings were analysed offline independently by two observers who were blind to the treatment.
For quantification of Arc mRNA, brains were removed 1 h after the last injection of drug or vehicle and snap frozen in isopentane cooled by dry ice. Brain tissue sections (12 μm) were cut in a cryostat (-21°C), thaw-mounted onto gelatine-subbed slides and stored (-80°C), then pretreated using standard methods. For in situ hybridisation, oligonucleotides complimentary to Arc mRNA were 3′-tail labelled with [35S]dATP and applied to each section in hybridization buffer (1×10−6 cpm/section). After overnight incubation at 37°C, sections were washed in buffer (3M NaCl and 300 mM citrate, pH 7) first at 55°C (3×20 min) then at room temperature (2×60 min). Sections were then allowed to dry overnight and exposed to Kodak Biomax MR film (Sigma–Aldrich) for 7 days at room temperature. Films were developed and analysed with a computerized image analysis system using densitometric software (MCID, Linton, UK).
Means were compared with pre-planned t-tests (one-tailed or paired as appropriate) using GraphPad Prism software. All data are presented as mean ± standard error of the mean.
FN3Competing Financial Interests Based on the therapeutic effects of Ebselen reported in this paper, all authors have filed the patent entitled Treatment of Bipolar disorder’: WO/2012/107735 A2.
Our research was supported by the Biotechnology and Biological Sciences Research Council through a Project Grant (BB/D012694/1) and a Follow-on Fund grant (BB/J021547/1). Nisha Singh was supported by a Departmental Scholarship, The Vice Chancellor’s and the Radhakrishnan Memorial Bequest Fund. Ivi Antoniadou was supported by a scholarship from the Onassis Foundation. We thank Daniel Rosen, Emma Wallace, Alex Lazare and Simon Hackett for help setting up the IMPase assay, Nathan Lack for advice on protein expression, Bob Sim for advice on protein purification, Edith Sim for use of protein purification equipment, Dave Smith and Fran Platt for advice on and use of the open field apparatus, Anna Nadali, Helen Storr and Tim Claridge for help with NMR and mass spectrometry and Michael Field for proofreading and editing.
|1.||Geddes JR,et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trialLancetYear: 201037538539520092882|
|2.||Dolgin E. The ultimate endpointNat. MedYear: 20121819019322310677|
|3.||McKnight RF,et al. Lithium toxicity profile: a systematic review and meta-analysisLancetYear: 201237972172822265699|
|4.||Cade JFJ. Lithium salts in the treatment of psychotic excitementMed. J. AustYear: 1949234935218142718|
|5.||Quiroz JA,Gould TD,Manji HK. Molecular effects of lithiumMol. IntervYear: 2004425927215471909|
|6.||O’Brien WT,Klein PS. Validating GSK3 as an in vivo target of lithium actionBiochem. Soc. TransYear: 2009371133113819754466|
|7.||Berridge MJ,Downes CP,Hanley MR. Neural and developmental actions of lithium: a unifying hypothesisCellYear: 1989594114192553271|
|8.||Belmaker RH,Bersudsky Y,Agam G,Levine J,Kofman O. How does lithium work on manic depression? Clinical and psychological correlates of the inositol theoryAnnu. Rev. MedYear: 19964747568712796|
|9.||Agam G,et al. Knockout mice in understanding the mechanism of action of lithiumBiochem. Soc. TransYear: 2009371121112519754464|
|10.||Cryns K,et al. IMPA1 is Essential for Embryonic Development and Lithium-Like Pilocarpine SensitivityNeuropsychopharmacologyYear: 20073367468417460611|
|11.||Baum AE,et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorderMol. PsychiatryYear: 20081319720717486107|
|12.||Purcell SM,et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorderNatureYear: 200946074875219571811|
|13.||Williams RSB,Cheng L,Mudge AW,Harwood AJ. A common mechanism of action for three mood-stabilizing drugsNatureYear: 200241729229512015604|
|14.||Atack JR. Inositol monophosphatase inhibitors--lithium mimetics?Med Res RevYear: 1997172152249057165|
|15.||Atack JR,Broughton HB,Pollack SJ. Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorderTrends NeurosciYear: 1995183433497482796|
|16.||Austin CP,Brady LS,Insel TR,Collins FS. NIH Molecular Libraries InitiativeScienceYear: 20043061138113915542455|
|17.||Copeland RA. Evaluation Of Enzyme Inhibitors In Drug Discovery: A Guide For Medicinal Chemists And PharmacologistsYear: 2005John Wiley and Sons|
|18.||Sarma BK,Mugesh G. Antioxidant activity of the anti-inflammatory compound ebselen: a reversible cyclization pathway via selenenic and seleninic acid intermediatesChemistryYear: 200814106031061418932179|
|19.||Haenen GR,De Rooij BM,Vermeulen NP,Bast A. Mechanism of the reaction of ebselen with endogenous thiols: dihydrolipoate is a better cofactor than glutathione in the peroxidase activity of ebselenMol. PharmacolYear: 1990374124222107391|
|20.||Knowles MR,et al. Bovine inositol monophosphatase. Modification, identification and mutagenesis of reactive cysteine residuesBiochem. JYear: 1992285Pt 24614681322134|
|21.||Singh N,et al. Cloning, expression, purification, crystallization and X-ray analysis of inositol monophosphatase from Mus musculus and Homo sapiensActa Crystallographica Section F Structural Biology and Crystallization CommunicationsYear: 201268|
|22.||Wagner G,Schuch G,Akerboom TP,Sies H. Transport of ebselen in plasma and its transfer to binding sites in the hepatocyteBiochem. PharmacolYear: 199448113711447945407|
|23.||Imai H,Masayasu H,Dewar D,Graham DI,Macrae IM. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemiaStrokeYear: 2001322149215411546910|
|24.||Agam G,et al. Lithium inhibitable enzymes in postmortem brain of bipolar patientsJ Psychiatr ResYear: 20033743344212849935|
|25.||Hansen RE,Roth D,Winther JR. Quantifying the global cellular thiol-disulfide statusProc. Natl. Acad. Sci. U.S.AYear: 200910642242719122143|
|26.||Barnes NM,Sharp TA. review of central 5-HT receptors and their functionNeuropharmacologyYear: 1999381083115210462127|
|27.||Friston KJ,Sharpley AL,Solomon RA,Cowen PJ. Lithium increases slow wave sleep: possible mediation by brain 5-HT2 receptors?Psychopharmacology (Berl.)Year: 1989981391402498958|
|28.||Goodwin GM,DeSouza RJ,Wood AJ,Green AR. Lithium decreases 5-HT1A and 5-HT2 receptor and α2-adrenoreceptor mediated function in micePsychopharmacologyYear: 1986904824873027734|
|29.||González-Maeso J,et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behaviorNeuronYear: 20075343945217270739|
|30.||Schloesser RJ,Martinowich K,Manji HK. Mood-stabilizing drugs: mechanisms of actionTrends NeurosciYear: 201235364622217451|
|31.||Nestler EJ,Hyman SE. Animal models of neuropsychiatric disordersNat. NeurosciYear: 2010131161116920877280|
|32.||Posser T,et al. Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic systemEur. J. PharmacolYear: 2009602859119026628|
|33.||O’Donnell KC,Gould TD. The behavioral actions of lithium in rodent models: leads to develop novel therapeuticsNeurosci Biobehav RevYear: 20073193296217532044|
|34.||Lynch E,Kil J. Development of Ebselen, a Glutathione Peroxidase Mimic, for the Prevention and Treatment of Noise-Induced Hearing LossSeminars in HearingYear: 200930047055|
|35.||Cryan JF,Holmes A. The ascent of mouse: advances in modelling human depression and anxietyNat Rev Drug DiscovYear: 2005477579016138108|
|36.||Jacobs D,Silverstone T. Dextroamphetamine-Induced Arousal in Human Subjects as a Model for ManiaPsychological MedicineYear: 1986163233293726006|
|37.||Lerer B,Globus M,Brik E,Hamburger R,Belmaker RH. Effect of treatment and withdrawal from chronic lithium in rats on stimulant-induced responsesNeuropsychobiologyYear: 19841128326738831|
|38.||Kofman O,Belmaker RH. Intracerebroventricularmyo-inositol antagonizes lithium-induced suppression of rearing behaviour in ratsBrain ResearchYear: 19905343453471963564|
|39.||Li X,Frye MA,Shelton RC. Review of pharmacological treatment in mood disorders and future directions for drug developmentNeuropsychopharmacologyYear: 2012377710121900884|
|40.||Scannell JW,Blanckley A,Boldon H,Warrington B. Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug DiscoveryYear: 201211191200|
|41.||Yamaguchi T,et al. Ebselen Study GroupEbselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trialStrokeYear: 19982912179445321|
|42.||Nogueira CW,Zeni G,Rocha JBT. Organoselenium and organotellurium compounds: toxicology and pharmacologyChem. RevYear: 20041046255628515584701|
|43.||Zarate CA Jr,et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot studyBipolar DisordYear: 2007956157017845270|
|44.||Schewe T. Molecular actions of ebselen--an antiinflammatory antioxidantGen. PharmacolYear: 199526115311697590103|
|45.||Lounkine E,et al. Large-scale prediction and testing of drug activity on side-effect targetsNatureYear: 201248636136722722194|
|46.||Frantz S. Drug discovery: playing dirtyNatureYear: 200543794294316222266|
|47.||Roth BL,Sheffler DJ,Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophreniaNature Reviews Drug DiscoveryYear: 20043353359|
|48.||Conn PJ,Roth BL. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settingsNeuropsychopharmacologyYear: 2008332048206018216778|
|49.||Singh J,Petter RC,Baillie TA,Whitty A. The resurgence of covalent drugsNat Rev Drug DiscovYear: 20111030731721455239|
|50.||Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactionsDrug Discov. TodayYear: 2003883283712963319|
|51.||Barf T,Kaptein A. Irreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksJ. Med. ChemYear: 2012556243626222621397|
|52.||Copeland RA,Pompliano DL,Meek TD. Drug-target residence time and its implications for lead optimizationNat Rev Drug DiscovYear: 2006573073916888652|
|53.||Insel TR,Sahakian BJ. Drug research: a plan for mental illnessNatureYear: 201248326922422245|
|54.||Schwab ME,Buchli AD. Drug research: plug the real brain drainNatureYear: 201248326726822422244|
|55.||Schoepp DD. Where will new neuroscience therapies come from?Nat Rev Drug DiscovYear: 20111071571621959271|
|56.||Collins FS. Reengineering Translational Science: The Time Is RightSci Transl MedYear: 2011390cm1790cm17|
|57.||Huang R,et al. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical GenomicsSci Transl MedYear: 2011380ps1680ps16|
|58.||Cavalla D. APT drug R&D: the right active ingredient in the right presentation for the right therapeutic useNat Rev Drug DiscovYear: 2009884985319713959|
|59.||McAllister G,et al. cDNA cloning of human and rat brain myo-inositol monophosphatase. Expression and characterization of the human recombinant enzymeBiochem. JYear: 1992284Pt 37497541377913|
|60.||Loo JA. Studying noncovalent protein complexes by electrospray ionization mass spectrometryMass Spectrom RevYear: 1997161239414489|
Previous Document: Sulphur-TiO(2) yolk-shell nanoarchitecture with internal void space for long-cycle lithium-sulphur b...
Next Document: Blood-clotting-inspired reversible polymer-colloid composite assembly in flow.